Natural history of medullary thyroid carcinoma in MEN 2 patients carrying a variant at codon 804 in the RET proto-oncogene: A study by the French Neuroendocrine Tumor Group (GTE)
Valentine Suteau , Maÿlis Lebeault , Martin Schlumberger , Mohamed Zalzali , Hélène Lasolle , Maëlle Le Bras , Gérard Chabrier , Isabelle Raingeard , Frédéric Castinetti , Philippe Caron , Cécile Ghander , Nicolas Chevalier , Delphine Mirebeau-Prunier , Vincent Rohmer , Patrice Rodien , Claire Briet
{"title":"Natural history of medullary thyroid carcinoma in MEN 2 patients carrying a variant at codon 804 in the RET proto-oncogene: A study by the French Neuroendocrine Tumor Group (GTE)","authors":"Valentine Suteau , Maÿlis Lebeault , Martin Schlumberger , Mohamed Zalzali , Hélène Lasolle , Maëlle Le Bras , Gérard Chabrier , Isabelle Raingeard , Frédéric Castinetti , Philippe Caron , Cécile Ghander , Nicolas Chevalier , Delphine Mirebeau-Prunier , Vincent Rohmer , Patrice Rodien , Claire Briet","doi":"10.1016/j.ando.2025.101705","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>RET</em> variants affecting codon 804 are part of the low-to-moderate risk group in the ATA classification, with indications for prophylactic thyroidectomy beyond age of 5<!--> <!-->years. However, aggressiveness seems to be variable. The objective of this study was to report a large cohort of French carriers of a pathogenic variant at codon 804 in the <em>RET</em> proto-oncogene.</div></div><div><h3>Methods</h3><div>Patients from 12 university hospitals with a <em>RET</em> 804 variant were recruited in this retrospective non-interventional French national study, from the French GTE-ENDOCAN-RENATEN database. Incidence and severity (TNM stage and calcitonin levels) of medullary thyroid carcinoma (MTC), phenotype-genotype correlation and clinical outcome were assessed.</div></div><div><h3>Results</h3><div>A total of 322 patients were analyzed. Index cases (<em>n</em> <!-->=<!--> <!-->65) had a median age at diagnosis of 57<!--> <!-->years (range: 46–66), and relatives (<em>n</em> <!-->=<!--> <!-->257) a median age of 37<!--> <!-->years (range: 18–51). Median first calcitonin measurement was 240<!--> <!-->ng/L (range: 79–1344) in index cases, and 6.7<!--> <!-->ng/L (range: 0–22) in relatives. In index cases, the pathogenic variant c.2410G>A (p.Val804Met) in <em>RET</em> was more frequent (80% of cases) than c.2410G>C or c.2410G>T (p.Val804Leu). MTC was multifocal, node-positive and metastatic in 64%, 51% and 20% of cases respectively. TNM stage, preoperative calcitonin level and male gender were predictive of persistent disease (defined by postoperative calcitonin<!--> <!-->><!--> <!-->5<!--> <!-->ng/L) (<em>P</em> <!--><<!--> <!-->0.001). Ten-year disease-free survival (DFS) was 61%. In total, 113 relatives were operated on: 62% with MTC and 34% with isolated C-cell hyperplasia (CCH); the youngest patients were aged 20 for MTC and 4<!--> <!-->years for CCH. Ten-year DFS was 90%.</div></div><div><h3>Conclusion</h3><div>The <em>RET</em> pathogenic variants affecting the codon 804 mainly led to low aggressiveness disease, with late presentation and prolonged DFS. We suggest surgery in relatives if calcitonin values are above 6<!--> <!-->ng/L, instead of 10<!--> <!-->ng/L. Long-term surveillance is mandatory, since recurrence remains possible several years after surgery.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 2","pages":"Article 101705"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales d'endocrinologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003426625000241","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
RET variants affecting codon 804 are part of the low-to-moderate risk group in the ATA classification, with indications for prophylactic thyroidectomy beyond age of 5 years. However, aggressiveness seems to be variable. The objective of this study was to report a large cohort of French carriers of a pathogenic variant at codon 804 in the RET proto-oncogene.
Methods
Patients from 12 university hospitals with a RET 804 variant were recruited in this retrospective non-interventional French national study, from the French GTE-ENDOCAN-RENATEN database. Incidence and severity (TNM stage and calcitonin levels) of medullary thyroid carcinoma (MTC), phenotype-genotype correlation and clinical outcome were assessed.
Results
A total of 322 patients were analyzed. Index cases (n = 65) had a median age at diagnosis of 57 years (range: 46–66), and relatives (n = 257) a median age of 37 years (range: 18–51). Median first calcitonin measurement was 240 ng/L (range: 79–1344) in index cases, and 6.7 ng/L (range: 0–22) in relatives. In index cases, the pathogenic variant c.2410G>A (p.Val804Met) in RET was more frequent (80% of cases) than c.2410G>C or c.2410G>T (p.Val804Leu). MTC was multifocal, node-positive and metastatic in 64%, 51% and 20% of cases respectively. TNM stage, preoperative calcitonin level and male gender were predictive of persistent disease (defined by postoperative calcitonin > 5 ng/L) (P < 0.001). Ten-year disease-free survival (DFS) was 61%. In total, 113 relatives were operated on: 62% with MTC and 34% with isolated C-cell hyperplasia (CCH); the youngest patients were aged 20 for MTC and 4 years for CCH. Ten-year DFS was 90%.
Conclusion
The RET pathogenic variants affecting the codon 804 mainly led to low aggressiveness disease, with late presentation and prolonged DFS. We suggest surgery in relatives if calcitonin values are above 6 ng/L, instead of 10 ng/L. Long-term surveillance is mandatory, since recurrence remains possible several years after surgery.
期刊介绍:
The Annales d''Endocrinologie, mouthpiece of the French Society of Endocrinology (SFE), publishes reviews, articles and case reports coming from clinical, therapeutic and fundamental research in endocrinology and metabolic diseases. Every year, it carries a position paper by a work-group of French-language endocrinologists, on an endocrine pathology chosen by the Society''s Scientific Committee. The journal is also the organ of the Society''s annual Congress, publishing a summary of the symposia, presentations and posters. "Les Must de l''Endocrinologie" is a special booklet brought out for the Congress, with summary articles that are always very well received. And finally, we publish the high-level instructional courses delivered during the Henri-Pierre Klotz International Endocrinology Days. The Annales is a window on the world, keeping alert clinicians up to date on what is going on in diagnosis and treatment in all the areas of our specialty.